Skip to main content
SpringerLink
Log in

The Design and Engineering of IgG-Like Bispecific Antibodies

  • Chapter
  • First Online:
Bispecific Antibodies

Abstract

Bispecific antibodies (BsAb) are capable of simultaneously targeting two distinct epitopes on the same or different antigens. Accumulating evidence indicates that BsAb may possess improved selectivity and therapeutic efficacy compared to their parental antibodies alone or in combination. Significant advancement has been made in the past years towards the generation and development of BsAb fragments. In contrast, the progress in successful design and production of full length IgG-like BsAb has been hampered by many factors, such as challenges in molecular design and formatting, low production yields, and poor stability. Recent progress in the field of antibody engineering has resulted in a number of encouraging novel approaches to optimize the biochemical and biophysical properties and the manufacturability of BsAb. This chapter reviews the current advances in design and engineering of the IgG-like BsAb in the context of their potential clinical applications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ahmad SA, Liu W, Jung YD, Fan F, Wilson M, Reinmuth N, Shaheen RM, Bucana CD, Ellis LM (2001) The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res 61:1255–1259

    PubMed  CAS  Google Scholar 

  • Alt M, Muller R, Kontermann RE (1999) Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. FEBS Lett 454:90–94

    Article  PubMed  CAS  Google Scholar 

  • Atwell S, Ridgway JB, Wells JA, Carter P (1997) Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol 270:26–35

    Article  PubMed  CAS  Google Scholar 

  • Beck A, Wurch T, Bailly C, Corvaia N (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10:345–352

    Article  PubMed  CAS  Google Scholar 

  • Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C, Fuh G (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323:1610–1614

    Article  PubMed  CAS  Google Scholar 

  • Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63:8912–8921

    PubMed  CAS  Google Scholar 

  • Chakravarti A, Loeffler JS, Dyson NJ (2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62:200–207

    PubMed  CAS  Google Scholar 

  • Chan AC, Carter PJ (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10:301–316

    Article  PubMed  CAS  Google Scholar 

  • Colcher D, Bird R, Roselli M, Hardman KD, Johnson S, Pope S, Dodd SW, Pantoliano MW, Milenic DE, Schlom J (1990) In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 82:1191–1197

    Article  PubMed  CAS  Google Scholar 

  • Coloma MJ, Morrison SL (1997) Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 15:159–163

    Article  PubMed  CAS  Google Scholar 

  • Cotton RG, Milstein C (1973) Letter: fusion of two immunoglobulin-producing myeloma cells. Nature 244:42–43

    Article  PubMed  CAS  Google Scholar 

  • Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, Huston JS (2010) SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel 23:195–202

    Article  PubMed  CAS  Google Scholar 

  • Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T, Lammerts van Bueren JJ, Bleeker WK, Parren PW, van de Winkel JG, Valerius T (2008) Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 68:4998–5003

    Article  PubMed  CAS  Google Scholar 

  • Dimasi N, Gao C, Fleming R, Woods RM, Yao XT, Shirinian L, Kiener PA, Wu H (2009) The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol 393:672–692

    Article  PubMed  CAS  Google Scholar 

  • Eigenbrot C, Randal M, Presta L, Carter P, Kossiakoff AA (1993) X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. J Mol Biol 229:969–995

    Article  PubMed  CAS  Google Scholar 

  • Els CK, Lauwereys M, Wyns L, Muyldermans S (2001) Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem 276:7346–7350

    Article  Google Scholar 

  • Ewert S, Honegger A, Pluckthun A (2004) Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. Methods 34:184–199

    Article  PubMed  CAS  Google Scholar 

  • FitzGerald K, Holliger P, Winter G (1997) Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris. Protein Eng 10:1221–1225

    Article  PubMed  CAS  Google Scholar 

  • Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, Ng SB, Born T, Retter M, Manchulenko K, Sweet H, Foltz IN, Wittekind M (2010) and Yan, W. Applications to bispecific molecules and monovalent IgG. J. Biol. Chem, Enhancing antibody Fc heterodimer formation through electrostatic steering effects

    Google Scholar 

  • He F, Hogan S, Latypov RF, Narhi LO, Razinkov VI (2010) High throughput thermostability screening of monoclonal antibody formulations. J Pharm Sci 99:1707–1720

    PubMed  CAS  Google Scholar 

  • Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23:1126–1136

    Article  PubMed  CAS  Google Scholar 

  • Holliger P, Prospero T, Winter G (1993) “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90:6444–6448

    Article  PubMed  CAS  Google Scholar 

  • Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM (2003) Domain antibodies: proteins for therapy. Trends Biotechnol 21:484–490

    Article  PubMed  CAS  Google Scholar 

  • Jespers L, Schon O, James LC, Veprintsev D, Winter G (2004) Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold. J Mol Biol 337:893–903

    Article  PubMed  CAS  Google Scholar 

  • Jordan JL, Arndt JW, Hanf K, Li G, Hall J, Demarest S, Huang F, Wu X, Miller B, Glaser S, Fernandez EJ, Wang D, Lugovskoy A (2009) Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules. Proteins 77:832–841

    Article  PubMed  CAS  Google Scholar 

  • Jung SH, Pastan I, Lee B (1994) Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3. Proteins 19:35–47

    Article  PubMed  CAS  Google Scholar 

  • Jung YD, Mansfield PF, Akagi M, Takeda A, Liu W, Bucana CD, Hicklin DJ, Ellis LM (2002) Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 38:1133–1140

    Article  PubMed  CAS  Google Scholar 

  • Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth CW, Matys ER, Little M (1999) Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 293:41–56

    Article  PubMed  CAS  Google Scholar 

  • Kobari M, Kullenberg B, Bjorkman A, Matsuno S, Ihse I, Axelson J (1998) The inhibitory effect of an EGF receptor-specific tyrosine kinase inhibitor on pancreatic cancer cell lines was more potent than inhibitory antibodies against the receptors for EGF and IGF I. Int J Pancreatol 24:85–95

    PubMed  CAS  Google Scholar 

  • Kontermann RE, Muller R (1999) Intracellular and cell surface displayed single-chain diabodies. J Immunol Methods 226:179–188

    Article  PubMed  CAS  Google Scholar 

  • Krane JF, Murphy DP, Carter DM, Krueger JG (1991) Synergistic effects of epidermal growth factor (EGF) and insulin-like growth factor I/somatomedin C (IGF-I) on keratinocyte proliferation may be mediated by IGF-I transmodulation of the EGF receptor. J Invest Dermatol 96:419–424

    Article  PubMed  CAS  Google Scholar 

  • Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K (2001) Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61:6624–6628

    PubMed  CAS  Google Scholar 

  • Lamszus K, Brockmann MA, Eckerich C, Bohlen P, May C, Mangold U, Fillbrandt R, Westphal M (2005) Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin Cancer Res 11:4934–4940

    Article  PubMed  CAS  Google Scholar 

  • Lu D, Kotanides H, Jimenez X, Zhou Q, Persaud K, Bohlen P, Witte L, Zhu Z (1999) Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2. J Immunol Methods 230:159–171

    Article  PubMed  CAS  Google Scholar 

  • Lu D, Jimenez X, Zhang H, Atkins A, Brennan L, Balderes P, Bohlen P, Witte L, Zhu Z (2003) Di-diabody: a novel tetravalent bispecific antibody molecule by design. J Immunol Methods 279:219–232

    Article  PubMed  CAS  Google Scholar 

  • Lu D, Jimenez X, Witte L, Zhu Z (2004a) The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody. Biochem Biophys Res Commun 318:507–513

    Article  PubMed  CAS  Google Scholar 

  • Lu D, Zhang H, Ludwig D, Persaud A, Jimenez X, Burtrum D, Balderes P, Liu M, Bohlen P, Witte L, Zhu Z (2004b) Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 279:2856–2865

    Article  PubMed  CAS  Google Scholar 

  • Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, Patel D, Kang X, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Zhu Z (2005) A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 280:19665–19672

    Article  PubMed  CAS  Google Scholar 

  • Mabry R, Lewis KE, Moore M, McKernan PA, Bukowski TR, Bontadelli K, Brender T, Okada S, Lum K, West J, Kuijper JL, Ardourel D, Franke S, Lockwood L, Vu T, Frank A, Appleby MW, Wolf A, Reardon B, Hamacher NB, Stevens B, Lewis P, Lewis KB, Gilbertson DG, Lantry M, Julien SH, Ostrander C, Chan C, Byrnes-Blake K, Brody J, Presnell S, Meengs B, Levin SD, Snavely M (2010) Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Protein Eng Des Sel 23:115–127

    Article  PubMed  CAS  Google Scholar 

  • Marvin JS, Zhu Z (2006) Bispecific antibodies for dual-modality cancer therapy: killing two signaling cascades with one stone. Curr Opin Drug Discov Devel 9:184–193

    PubMed  CAS  Google Scholar 

  • Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P (1998) An efficient route to human bispecific IgG. Nat Biotechnol 16:677–681

    Article  PubMed  CAS  Google Scholar 

  • Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, Huang F, Phan S, Gao S, Doern A, Farrington GK, Lugovskoy A, Joseph I, Bailly V, Wang X, Garber E, Browning J, Glaser SM (2009) Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. MAbs 1:128–141

    Article  PubMed  Google Scholar 

  • Miller K, Meng G, Liu J, Hurst A, Hsei V, Wong WL, Ekert R, Lawrence D, Sherwood S, DeForge L, Gaudreault J, Keller G, Sliwkowski M, Ashkenazi A, Presta L (2003) Design, construction, and in vitro analyses of multivalent antibodies. J Immunol 170:4854–4861

    PubMed  CAS  Google Scholar 

  • Miller BR, Glaser SM, Demarest SJ (2009) Rapid screening platform for stabilization of scFvs in Escherichia coli. Methods Mol Biol 525:279–289, xiv

    Article  PubMed  CAS  Google Scholar 

  • Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, Croner LJ, Wang N, Amatucci A, Michaelson JS, Glaser SM (2010) Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 23(7):549–557

    Article  PubMed  CAS  Google Scholar 

  • Muller D, Kontermann RE (2010) Bispecific antibodies for cancer immunotherapy: current perspectives. BioDrugs 24:89–98

    Article  PubMed  Google Scholar 

  • Muyldermans S, Atarhouch T, Saldanha J, Barbosa JA, Hamers R (1994) Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng 7:1129–1135

    Article  PubMed  CAS  Google Scholar 

  • Nahta R, Hung MC, Esteva FJ (2004) The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64:2343–2346

    Article  PubMed  CAS  Google Scholar 

  • Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, Satoh M, Shitara K (2006) Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region. J Biochem 140:359–368

    Article  PubMed  CAS  Google Scholar 

  • Nisonoff A, Rivers MM (1961) Recombination of a mixture of univalent antibody fragments of different specificity. Arch Biochem Biophys 93:460–462

    Article  PubMed  CAS  Google Scholar 

  • Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD (2002) Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA 99:11346–11350

    Article  PubMed  CAS  Google Scholar 

  • Orcutt KD, Ackerman ME, Cieslewicz M, Quiroz E, Slusarczyk AL, Frangioni JV, Wittrup KD (2010) A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel 23:221–228

    Article  PubMed  CAS  Google Scholar 

  • Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, Kragh M (2010) Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 70:588–597

    Article  PubMed  CAS  Google Scholar 

  • Penar PL, Khoshyomn S, Bhushan A, Tritton TR (1997) Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgery 40:141–151

    PubMed  CAS  Google Scholar 

  • Ridgway JB, Presta LG, Carter P (1996) ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 9:617–621

    Article  PubMed  CAS  Google Scholar 

  • Riechmann L, Muyldermans S (1999) Single domain antibodies: comparison of camel VH and camelised human VH domains. J Immunol Methods 231:25–38

    Article  PubMed  CAS  Google Scholar 

  • Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von MM, Shchaveleva I, Simmons HH, Marks JD, Adams GP (2008) Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 99:1415–1425

    Article  PubMed  CAS  Google Scholar 

  • Saerens D, Ghassabeh GH, Muyldermans S (2008) Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol 8:600–608

    Article  PubMed  CAS  Google Scholar 

  • Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, Gonen M, Quinones M, Morse M, Chen HX (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25:4557–4561

    Article  PubMed  CAS  Google Scholar 

  • Shen J, Vil MD, Jimenez X, Iacolina M, Zhang H, Zhu Z (2006) Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies. J Biol Chem 281:10706–10714

    Article  PubMed  CAS  Google Scholar 

  • Shen J, Vil MD, Jimenez X, Zhang H, Iacolina M, Mangalampalli V, Balderes P, Ludwig DL, Zhu Z (2007) Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies. J Immunol Methods 318:65–74

    Article  PubMed  CAS  Google Scholar 

  • Tonra JR, Corcoran E, Deevi DS, Steiner P, Kearney J, Li H, Ludwig DL, Zhu Z, Witte L, Surguladze D, Hicklin DJ (2009) Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models. Anticancer Res 29:1999–2007

    PubMed  CAS  Google Scholar 

  • Volk WA, Bizzini B, Snyder RM, Bernhard E, Wagner RR (1984) Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule. Infect Immun 45:604–609

    PubMed  CAS  Google Scholar 

  • Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G (1989) Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341:544–546

    Article  PubMed  CAS  Google Scholar 

  • Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10:317–327

    Article  PubMed  CAS  Google Scholar 

  • Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M, Cauerhff A, Danquah W, Rissiek B, Scheuplein F, Schwarz N, Adriouch S, Boyer O, Seman M, Licea A, Serreze DV, Goldbaum FA, Haag F, Koch-Nolte F (2009) Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol 198:157–174

    Article  PubMed  CAS  Google Scholar 

  • Williams BR, Sharon J (2002) Polyclonal anti-colorectal cancer Fab phage display library selected in one round using density gradient centrifugation to separate antigen-bound and free phage. Immunol Lett 81:141–148

    Article  PubMed  CAS  Google Scholar 

  • Williams BR, Sompuram SR, Sharon J (2002) Generation of anti-colorectal cancer fab phage display libraries with a high percentage of diverse antigen-reactive clones. Comb Chem High Throughput Screen 5:489–499

    Article  PubMed  CAS  Google Scholar 

  • Worn A, Pluckthun A (2001) Stability engineering of antibody single-chain Fv fragments. J Mol Biol 305:989–1010

    Article  PubMed  CAS  Google Scholar 

  • Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, Davis-Taber R, Kunes Y, Fung E, Schwartz A, Sakorafas P, Gu J, Tarcsa E, Murtaza A, Ghayur T (2007) Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 25:1290–1297

    Article  PubMed  CAS  Google Scholar 

  • Xie Z, Guo N, Yu M, Hu M, Shen B (2005) A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis. J Immunol Methods 296:95–101

    Article  PubMed  CAS  Google Scholar 

  • Ye D, Mendelsohn J, Fan Z (1999) Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 18:731–738

    Article  PubMed  CAS  Google Scholar 

  • Zapata G, Ridgway JB, Mordenti J, Osaka G, Wong WL, Bennett GL, Carter P (1995) Engineering linear F(ab’)2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity. Protein Eng 8:1057–1062

    Article  PubMed  CAS  Google Scholar 

  • Zhu Z, Zapata G, Shalaby R, Snedecor B, Chen H, Carter P (1996) High level secretion of a humanized bispecific diabody from Escherichia coli. Biotechnology (N Y) 14:192–196

    Article  CAS  Google Scholar 

  • Zhu Z, Presta LG, Zapata G, Carter P (1997) Remodeling domain interfaces to enhance heterodimer formation. Protein Sci 6:781–788

    Article  PubMed  CAS  Google Scholar 

  • Zuo Z, Jimenez X, Witte L, Zhu Z (2000) An efficient route to the production of an IgG-like bispecific antibody. Protein Eng 13:361–367

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Protein Sciences and Design, Novartis Biologics, Novartis Pharma AG, 200 Technology Square, Cambridge, MA, 02139, USA

    Pei Jin

  2. Kadmon Pharmaceuticals LLC, 400 Madison Avenue, 11th Floor, New York, NY, 10017, USA

    Zhenping Zhu

Authors
  1. Pei Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhenping Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhenping Zhu .

Editor information

Editors and Affiliations

  1. Inst. Zellbiologie und Immunologie, Universität Stuttgart, Allmandring 31, Stuttgart, 70569, Germany

    Roland E. Kontermann

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Jin, P., Zhu, Z. (2011). The Design and Engineering of IgG-Like Bispecific Antibodies. In: Kontermann, R. (eds) Bispecific Antibodies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-20910-9_9

Download citation

Publish with us

Policies and ethics

Search

Navigation